

Grifols appoints Rahul Srinivasan as new Chief Financial Officer

- *Srinivasan will lead Grifols' global financial organization, taking over from Alfredo Arroyo, who recently announced his retirement after 17 years of service*
- *He brings extensive experience in senior finance leadership roles encompassing advisory, global capital markets, risk management, financial planning and analysis, compliance, governance and audit*
- *Srinivasan recently served as Head of EMEA Leveraged Finance and Capital Markets at Bank of America, where the team drove significant revenue growth under his leadership*
- *Srinivasan, who will start on September 16, 2024, will be part of Grifols' executive committee and report to CEO Nacho Abia and will work alongside Arroyo during a transition period to ensure a smooth transfer of duties*

Barcelona, Spain, July 4, 2024 – Grifols (MCE:GRF, MCE: GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announced that Rahul Srinivasan will be its new Chief Financial Officer (CFO).

Srinivasan will lead the company's overall financial function including planning, treasury, tax, reporting, and investor relations and sustainability. He will also be responsible for implementing effective cash-flow strategies and driving debt-management plans. He succeeds Alfredo Arroyo, who with 17 years of dedicated service to Grifols and having driven pivotal changes has recently decided to retire.

"I am thrilled to welcome Rahul to our team. He brings a wealth of knowledge and experience together with a proven track record of success," said **Nacho Abia, Grifols CEO**. "Rahul's insights, deep knowledge of corporate finance and broad experience navigating dynamic capital markets, as well as his strong performance-oriented culture, make him an extremely valuable asset for our next chapter of growth."

Srinivasan has held numerous senior leadership roles with over 25 years of financial services experience at KPMG, Credit Suisse and Bank of America, spanning audit & assurance services, transaction services and corporate finance, mergers and acquisitions and capital markets.

Most recently he was the Head of EMEA Leveraged Finance and Capital Markets at Bank of America, where the team drove significant revenue growth under his leadership.

GRIFOLS

“I look forward to partnering with Nacho, his senior management team and the Board of this venerable institution that has made a huge difference to people’s lives with its portfolio of life-changing medicines across a wide range of therapeutic areas,” said Rahul Srinivasan.

Srinivasan will assume his new role on September 16, 2024, and will work alongside Arroyo during a transition period to ensure a smooth transfer of duties.

He is a distinguished Fellow of the Institute of Chartered Accountants in England and Wales (ICAEW), a Business Mathematics and Statistics graduate from The London School of Economics and Political Sciences and was awarded a fully sponsored Executive MBA from ENPC School of International Management (Paris, France).

MEDIA CONTACTS:

Grifols Press Office

media@grifols.com

Tel. +34 93 571 00 02

Spain

Duomo Comunicación

Tel.: +34 91 311 92 89 – 91 311 92 90

Raquel Lumbreras

raquel_lumbreras@duomocomunicacion.com

Tel.: +34 659 57 21 85

Borja Gómez

borja_gomez@duomocomunicacion.com

Tel.: 650 40 22 25

Investor contact:

Investor Relations

inversores@grifols.com - investors@grifols.com

Tel.: +34 93 571 02 21

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and our ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world’s largest with over 390 across North America, Europe, Africa and the Middle East and China.

GRIFOLS

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. We provide high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 24,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information, please visit grifols.com

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are "future projections and assumptions". Words and expressions such as "believe", "hope", "anticipate", "predict", "expect", "intend", "should", "will seek to achieve", "it is estimated", "future" and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.